New targeted therapy battles recurrent ovarian cancer in major trial
NCT ID NCT07504588
First seen Apr 04, 2026 · Last updated Apr 10, 2026 · Updated 1 time
Summary
This study is for people whose ovarian cancer has returned after initially responding to platinum-based chemotherapy and has progressed while on a specific type of maintenance therapy (a PARP inhibitor). It aims to see if a newer drug combination (sacituzumab govitecan plus bevacizumab) works better than the current standard treatment (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) at controlling the cancer for longer. The main goal is to compare how long patients live without their cancer getting worse on the two different treatment plans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-SENSITIVE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.